2022-502030-12-01RecruitingPhase 1
This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 4 (estimated)
- First submitted
- 26 Oct 2022
- Start date
- 13 Oct 2022
- Lead sponsor
- Cell4Cure AB
- Diseases
- Haemophilia
- EU CT number
- 2022-502030-12-01
- EudraCT number
- 2021-000608-39
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 4
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital HF | Oslo | Norway | Recruiting |
| Lund University Hospital | Lund | Sweden | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.